Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018-2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
- PMID: 37783722
- PMCID: PMC10545822
- DOI: 10.1038/s41598-023-43434-x
Factors associated with poorer quality of life in people living with HIV in southwestern France in 2018-2020 (ANRS CO3 AQUIVIH-NA cohort: QuAliV study)
Abstract
We evaluated people living with Human Immunodeficiency Virus' (PLWH) quality of life (QoL) and assessed whether their demographic, disease-related, socioeconomic, or behavioral characteristics were associated with poorer QoL. ANRS CO3 AQUIVIH-NA cohort participants (Nouvelle Aquitaine, France) were recruited to a cross-sectional study (2018-2020) and their QoL assessed (WHOQOL-BREF). We calculated median (Q1, Q3) QoL domain scores and assessed factors associated with poorer median QoL using bivariable and multivariable quartile regression. Of the 965 PLWH included, 98.4% were on antiretroviral therapy, 94.7% were virally-suppressed, 63.5% reported good/very good QoL. Median scores (0-100) were highest for physical (69;Q1, Q3: 56, 81) and environmental (69; 56, 75) QoL and lowest for social (56; 44, 69) and psychological (56; 44, 69) QoL. PLWH with ≥ 3 comorbidities, HIV-related stigma, or income of < 1500€/month had poorer median adjusted physical, psychological, social, and environmental QoL scores compared to reference groups. While more than half of PLWH reported good/very good QoL, we have not achieved good QoL in 90% of PLWH. Multi-morbidity, HIV-related stigma, and social determinants were consistently and independently associated with poorer QoL. Addressing structural factors in addition to those indirectly related to HIV is required to attain good QoL in all PLWH.
© 2023. Springer Nature Limited.
Conflict of interest statement
MH, DN, SF, OL, NR, PD, CC, EL, PR, FD, and LW have no relevant financial or nonfinancial competing interests to disclose. DB received speaking fees from Gilead Sciences and ViiV Healthcare and was compensated as an expert on a Gilead Sciences advisory board outside the submitted work. FB reports non-financial support from Gilead Sciences, Janssen, ViiV Healthcare, and MSD, and personal fees from Gilead Sciences, Janssen, ViiV Healthcare, and MSD outside the submitted work.
Figures
References
-
- UNAIDS. 90–90–90—An ambitious treatment target to help end the AIDS epidemic (2014).
-
- Lazarus, J. V., Safreed-Harmon, K. Depicting a New Target For the HIV Response: How Do You See the ‘Fourth 90’? Barcelona; 2018. Available from: https://www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/visuall... [Last Accessed; 4 February 2021].
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
